Sequoia Financial Advisors LLC grew its stake in shares of Altimmune, Inc. (NASDAQ:ALT – Free Report) by 34.5% in the fourth ...

Altimmune (NASDAQ:ALT – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research ...

We recently shared a list of 10 Best Short Squeeze Stocks To Buy According to Analysts. In this article, we will see how ...

Explore the promising potential of Altimmune, Inc.'s Pemvidutide in NASH, AUD, & obesity treatment, with key trials underway.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Bullish option flow detected in Altimmune (ALT) with 8,561 calls trading, 3x expected, and implied vol increasing almost 4 points to 114.21%.

The company unveiled plans last week to test its GLP-1/glucagon dual receptor agonist in alcohol use disorder and ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Shares of Altimmune (NASDAQ:ALT) traded sharply higher on Friday after the obesity drug developer generated buyout rumors on ...

Altimmune Inc. (NASDAQ:ALT) jumped 13% amid takeover speculation for the pharmaceutical firm. There's speculation that the ...